Today: 19 November 2025
Subscribe
Browse Category

Pharma News News 17 September 2025 - 11 October 2025

Quoin Pharma (QNRX) Stock Skyrockets 150% on Funding Deal – What’s Next?

Quoin Pharma (QNRX) Stock Skyrockets 150% on Funding Deal – What’s Next?

(Source: Nasdaq/GlobeNewswire, Reuters, TipRanks, Finviz, company filings.) Company Overview: Rare Disease Focus and Pipeline Progress Quoin Pharmaceuticals Ltd. is a clinical-stage biotech specializing in rare dermatological diseases. Headquartered in Ashburn, VA, Quoin’s mission is to deliver the first approved therapies for conditions that currently have none. “We remain fully focused on delivering the first approved therapy for Netherton Syndrome,” said CEO Dr. Michael Myers globenewswire.com. The company’s pipeline comprises three main product candidates targeting multiple orphan indications finviz.com: Until recently, Quoin had additional assets (QRX004 for epidermolysis bullosa, and QRX007 for Netherton) but shelved those programs in mid-2025 to concentrate
11 October 2025
 ·  ·  ·  ·  · 
Bristol Myers Snaps Up Orbital Therapeutics in $1.5B Biotech Power Play

Bristol Myers Snaps Up Orbital Therapeutics in $1.5B Biotech Power Play

In-Depth Analysis BMS’s acquisition of Orbital Therapeutics marks a deliberate push into autoimmune disease treatment via advanced cell therapy. Orbital, founded in 2022 by leaders in RNA and immunology, has built a proprietary RNA platform combining circular and linear RNA engineering with sophisticated lipid nanoparticle (LNP) delivery news.bms.com fiercebiotech.com. Its lead program, OTX-201, is designed as an in vivo CAR‑T: instead of harvesting and engineering cells outside the body, Orbital will inject circular RNA encoding a CD19-directed CAR into the patient, so the patient’s own T cells become the “manufacturers” of CAR‑T cells in situ news.bms.com orbitaltx.com. This approach could
10 October 2025
 ·  ·  ·  ·  · 
Intellia Therapeutics Stock Soars on Gene-Editing Breakthrough – Analysts Eye 70–100% Upside

Intellia Therapeutics Stock Soars on Gene-Editing Breakthrough – Analysts Eye 70–100% Upside

Intellia Background and Pipeline Intellia was an early pioneer of in-vivo CRISPR therapy. Based in Cambridge, MA, it was among the first to administer CRISPR-Cas9 therapies directly into patients ts2.tech. In 2021 Intellia reported the first clinical proof that in-body CRISPR editing could work – a single injection dramatically lowered the disease protein (transthyretin) in ATTR amyloidosis patients ts2.tech. Today, the company’s focus is on curative gene edits in severe diseases. Its lead programs are NTLA-2001 (nexiguran ziclumeran) for transthyretin amyloidosis (ATTR) and NTLA-2002 (lonvoguran ziclumeran) for hereditary angioedema (HAE) ts2.tech ts2.tech. Both use CRISPR delivered via lipid nanoparticles to
9 October 2025
 ·  ·  ·  ·  · 
Dyne Therapeutics Skyrockets on Breakthrough Data – Inside the Surge, Financials & 2026 Catalysts

Dyne Therapeutics Skyrockets on Breakthrough Data – Inside the Surge, Financials & 2026 Catalysts

Recent Stock Performance & Surge on Data Dyne Therapeutics’ stock has been on a tear following its latest clinical breakthroughs. Shares jumped 10–11% intraday on October 7, 2025, after the company reported positive one-year results from a key trial, lifting the stock to about $14.02 by mid-day marketbeat.com marketbeat.com. This rally builds on a strong upward trend in recent months – the stock traded below $8 in spring 2025, so it has nearly doubled since then. Trading volume actually dipped on the spike (about 331,000 shares vs. a 2.6 million average), indicating the price jolt came on limited activity marketbeat.com
7 October 2025
 ·  ·  ·  ·  · 
Spruce Biosciences Skyrockets on FDA Breakthrough – Will SPRB’s Rally Last or Fade?

Spruce Biosciences (SPRB) Skyrockets 1,300% on FDA Breakthrough – Inside the Stock Surge, Pipeline & Outlook (Oct 2025)

Stock Performance & Financial Metrics (as of Oct 7, 2025) Spruce Biosciences’ stock chart for 2025 looks like a hockey stick – mostly flat/down all year and then vertical in October. On Monday, Oct 6, SPRB opened around $8.60 and skyrocketed to $130.40 by the close (+1,378%) after the FDA news. The 52-week high was shattered in the process (previously the stock had been languishing below $2 pre-split, equivalent to <$150 post-split). Volume surged into the tens of millions of shares, far exceeding the tiny float, as investors clamored for a piece of the action. The rally continued after hours
7 October 2025
 ·  ·  ·  · 
Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Cidara Therapeutics (CDTX) Stock and Company Update as of September 24, 2025 Stock Performance & Technical Analysis Cidara’s stock has been on a tear in 2025, delivering triple-digit percentage gains. Year-to-date, CDTX has risen about +173% as of late September investing.com, driven by upbeat trial results and investor enthusiasm for its flu program. The stock recently surged over 20% in one day after the Phase 3 acceleration news, reaching an intraday high of approximately $87.75 on Sept. 24 marketbeat.com marketbeat.com. This is effectively a new 52-week (and all-time) high, far above its 52-week low of ~$10 marketbeat.com. By comparison, Cidara’s market capitalization now stands around $2.0–2.3 billion at these prices
24 September 2025
 ·  ·  ·  ·  · 
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly’s Weight-Loss Pill Sheds Pounds Fast—But Hits a Plateau: What New Trial Results Mean for the Obesity Drug Race

Trial Results: Big Early Losses, Then Weight Loss Levels Off This highly anticipated trial put Lilly’s oral GLP-1 drug, orforglipron, to the test in a large group of adults struggling with obesity. The study enrolled 3,127 overweight or obese participants (none had diabetes, but all had weight-related health issues) and randomly assigned them to various daily doses of the pill or a placebo for 72 weeks reuters.com. The outcomes were encouraging yet mixed. Patients on the highest dose (36 mg daily) lost on average about 11–12% of their starting body weight by week 72 theguardian.com. In practical terms, that’s roughly
17 September 2025
 ·  ·  ·  ·  ·  · 
1 2 3
Go toTop